Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-06-22
2009-12-29
Spector, Lorraine (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S145100, C435S070210
Reexamination Certificate
active
07638604
ABSTRACT:
Antibodies and antigen-binding fragments thereof that bind interleukin-22 (IL-22), in particular, human IL-22, and their uses in regulating IL-22-associated immune responses are disclosed. The antibodies disclosed herein are useful in diagnosing, preventing, or treating IL-22-associated immune disorders, e.g., autoimmune disorders (e.g., arthritis).
REFERENCES:
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5536637 (1996-07-01), Jacobs
patent: 5674487 (1997-10-01), Smith et al.
patent: 5837232 (1998-11-01), DeWaal Malefyt et al.
patent: 5863796 (1999-01-01), Moore et al.
patent: 6225117 (2001-05-01), Gately et al.
patent: 6274710 (2001-08-01), Dumoutier et al.
patent: 6331613 (2001-12-01), Dumoutier et al.
patent: 6359117 (2002-03-01), Dumoutier et al.
patent: 6551799 (2003-04-01), Gurney et al.
patent: 2001/0006637 (2001-07-01), Akahoshi et al.
patent: 2001/0024652 (2001-09-01), Dumoutier et al.
patent: 2002/0012669 (2002-01-01), Presnell et al.
patent: 2002/0102723 (2002-08-01), Gurney et al.
patent: 2002/0187523 (2002-12-01), Tang et al.
patent: 2003/0012788 (2003-01-01), Renauld et al.
patent: 2003/0099649 (2003-05-01), Fouser et al.
patent: 2003/0157106 (2003-08-01), Jacobs et al.
patent: 2003/0170823 (2003-09-01), Presnell et al.
patent: 2004/0023341 (2004-02-01), Xu et al.
patent: 2004/0110189 (2004-06-01), Dumoutier et al.
patent: 2004/0152125 (2004-08-01), Presnell et al.
patent: 2004/0180399 (2004-09-01), Renauld et al.
patent: WO 94/01548 (1994-01-01), None
patent: WO 99/61617 (1999-12-01), None
patent: WO 00/24758 (2000-05-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 00/73457 (2000-12-01), None
patent: WO 00/77037 (2000-12-01), None
patent: WO 01/46422 (2001-06-01), None
patent: WO 02/10393 (2002-02-01), None
patent: WO 02/16611 (2002-02-01), None
patent: WO 02/068476 (2002-09-01), None
Compact Oxford English Dictionary entry for “composition”. http://www.askoxford.com/concise—oed/composition?view=uk. Accessed Sep. 15, 2007.
R&D Systems, Catalog NR, AF582, XP002307633, “Anti-Mouse IL-22 Antibody”, Aug. 22, 2002.
Kotenko, Sergei, “The Family of IL-10-Related Cytokines and Their Receptors: Related, But To What Extent?”, Cytokine and Growth Factor Reviews, vol. 13, No. 3, Jun. 2002, pp. 223-240.
Dumoutier, L., et al, “Human Interleukin-10-Related T Cell-Derived Inducible Factor: Molecular Cloning and Functional Characterization as an Hepatocyte-Stimulating Factor”, PNAS, vol. 97, No. 18, Aug. 29, 2000, pp. 10144-10149.
Radaeva, Svetlana, et al, “Interleukin 22 (IL-22) Plays a Protective Role in T Cell-Mediated Murine Hepatitis: IL-22 is a Survival Factor for Hepatocytes via STAT3 Activation”, Hepatology, vol. 39, No. 5, May 2004, pp. 1332-1342.
Resmini, Christine, et al, “An Anti-Murine IL-22 Monoclonal Antibody Decreases Disease Severity in a Murine Model of Collagen Induced Arthritis”, European Cytokine Network, vol. 14, No. Supplement 3, Sep., 2003, p. 129 and Annual Meeting of the International Cytokine Society; Dublin, Ireland, Sep. 20-24, 2003, ISSN: 1148-5493.
Li, J., et al, “Temporal Associations Between Interleukin 22 and the Extracellular Domains of IL-22R and IL-10R2”, International Immunopharmacology, Elsevier, Amsterdam, NL, vol. 4, No. 5, May 2004, pp. 693-708.
International Search Report for International Application No. PCT/US04/020833.
Bork, P., Genome Research 10:398-400, 2000.
Doerks, et al, Trends in Genetics 14:248-250, 1998.
Smith, et al, Nature Biotechnology 15:1222-1223, 1997.
Brenner, S.E., Trends in Genetics 15:132-133, 1999.
Mahairas, et al., PNAS, USA, 96(17) 9739-9744 (1999).
Simon L.S., et al (Jun., 2000), New and future drug therapies for rheumatoid arthritis, Rheumatology 39:36-42.
Liorente L., et al. (2000), Clinical and Biological Effects of Anti-Interleukin-10 Monoclonal Antibody Administration in Systemic Lupus Erythematosus, Arthritis & Rheumatism 43(8): 1790-1800.
van den Berg, W. (1998), Joint Inflammation and Cartilage Destruction May Occur Uncoupled, Springer Semin. Immunopathol. 20:149-164.
International Search Report for International Application No. PCT/US02/05684.
International Search Report for International Application No. PCT/US00/11479.
European Search Report issued in EP Application No. 00928535.4-Jul. 14, 2004.
Dumoutier, L., et al: “Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), A novel cytokine structurally related to IL-10 and Inducible by IL-9” Journal of Immunology, Blackwell Scientific Publications, GB, vol. 164, 2000, pp. 1814-1819.
Xie, M-H et al: “Interleukin (IL)-22, a Novel Human Cytokine that Signals Through the Interferon Receptor-Related Proteins CRF2-4 and IL-22R” Journal of Biological Chemistry, vol. 275, No. 40, Oct. 6, 2000, pp. 31335-31339.
Kotenko, Sergei V. et al: “Identification of the Functional Interleukin-22 (IL-22) receptor complex. The IL-10R2 Chain (IL-10Rbeta) is a Common Chain of Both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) Receptor Complexes” Journal of Biological Chemistry, vol. 276, No. 4, Jan. 26, 2001, pp. 2725-2732.
Dumoutier, L., et al: “IL-TIF induces acute phase reactant production by hepatocytes through IL-10Rbeta” Immunology Letters, vol. 73, No. 2-3 Sep. 2000, p. 261.
Lambert, A., et al: “Novel cytokine IL-22 administered by adenovirus vector or as recombinant purified protein induces acute-phase responses and renal tubular basophilia in female C57BL/6 mice.” Toxicologic Pathology, vol. 29, No. 6, Nov. 2001, p. 712.
Mahairas G., et al Database EST. Accession No. AQ104025 Aug. 28, 1998.
Waterston R., et al Database GenEmbl. Accession No. AC006734 Feb. 25, 1999.
Wilson R., et al J. Mol. Biol. 261:155-172, 1996.
Bork, et al, Trends in Genetics 12:425-427, 1996.
Vukicevic, et al, PNAS USA 93:9021-9026, 1996.
Massague J. Cell 49:437-38, 1987.
Philbeam, et al Bone 14:717-720, 1993.
Skolnick, et al Trends in Biotech 18:34-39, 2000.
Syrbe, et al (1999) Springer Seminars in Immunopathology, 21:263-85.
Dumoutier, L., et al GenBank Accession No. NM—016971 for mus musculus interleukin 10-related T cell-derived inducible factor (Iltif). Jun. 8, 2000.
Aoki, I., et al. “Comparison of the amino acid and nucleotide sequences between human and two guinea pit major basic proteins,” FEBS Lett. 282(1):56-60, 1991.
Dumoutier, L., et al., “IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes,” Genes lmmun. 1:488-494, 2000.
Ozaki, T., et al GenBank Accession No. D13973 for Dictyostelium Discoideum DNA for Dp87 protein, 1993. Feb. 1, 2000.
Aoki, I., et al GenBank Accession No. P35709 for Eosinophil Granule Major Basic Protein 2 Percursor (mbp-2). May 30, 2000.
Xie, M., et al GenBank Accession No. AF279437 for Homo Sapiens Interleukin 22 (IL22). Oct. 9, 2000.
Dumoutier, L., et al GenBank Accession No. AJ294727 for Mus musculus ILTIFa gene for IL TIE alpha protein (IL-21), exons 1a 5. Dec. 21, 2000.
Dumoutier, L., et al GenBank Accession No. NP—065386 for Interleukin 22; interleukin 21; IL-10-related T-cell-derived inducible factor (homo sapiens). Nov. 2, 2000.
Ozaki, T., et al, “Developmental regulation of transcription of a novel prespore-specific gene (Dp87) in Dictyostelium discoideum,” Development. 117(4): 1299-308, 1993.
Sambrook, J., et al Molecular Cloning. A Laboratory Manual, 2d ed. Cold Spring Harbor Laboratory Press, 1989, Ch. 17.
Fouser Lynette
Li Jing
Pittman Debra D.
Tan Xiang-Yang
Tomkinson Kathleen N.
Genetics Institute LLC
Latimer and Mayberry IP Law, LLP
Spector Lorraine
Stoica Elly-Gerald
LandOfFree
Monoclonal antibodies against interleukin-22 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against interleukin-22, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against interleukin-22 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4066051